Vertex Pharmaceuticals
VRTX
$477.10
-0.95%
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for serious diseases, with a core focus on cystic fibrosis (CF) therapies like Trikafta/Kaftrio, Kalydeco, and Alyftrek. As the undisputed leader in CF treatment, Vertex holds a dominant market position with a near-monopoly in the space, generating over $12 billion in annual revenue from its CF franchise. The current investor narrative centers on Vertex's strategic diversification beyond CF, highlighted by the recent $10 billion acquisition of Crinetics Pharmaceuticals to bolster its pipeline, positive Phase 3 data for a novel kidney drug targeting APOL1-mediated diseases, and the commercial ramp of Casgevy, a gene-editing therapy for sickle cell disease and beta thalassemia. These catalysts are driving debate about whether Vertex can replicate its CF success in new therapeutic areas and sustain long-term growth.…
VRTX
Vertex Pharmaceuticals
$477.10
Related headlines
Investment Opinion: Should I buy VRTX Today?
Rating: Buy. Thesis: Vertex offers a rare combination of a high-margin, dominant CF franchise providing stable cash flows, plus a pipeline of high-potential catalysts in kidney disease and gene therapy that could drive the next growth phase. The consensus analyst rating is Buy (1.68/5) with an average target of $554.91, implying 16.2% upside.
Supporting Evidence: Vertex's trailing P/E of 29.32x is justified by a net margin of 34.5% (vs. industry ~15%) and ROE of 21.2%. Revenue grew 7.82% YoY in Q1 2026, with gross margins of 86.85% and operating margins of 38.1% (up from 22.7% a year ago). Free cash flow of $3.71 billion provides a 3.2% FCF yield, reasonable for a growth biotech. The forward P/E of 22.40x is in line with the industry average, suggesting the market is pricing in expected earnings growth of ~31%.
Risks & Conditions: The biggest risks are pipeline failure (kidney drug or Casgevy), CF growth deceleration below 5%, and integration issues with Crinetics. This Buy rating would downgrade to Hold if revenue growth falls below 5% or if the kidney drug fails to get FDA approval. It would upgrade to Strong Buy if the stock pulls back to $430 (20x forward P/E) or if pipeline catalysts accelerate. Overall, Vertex appears fairly valued relative to its growth prospects, with the forward P/E near the industry average, but the premium on trailing earnings reflects justified confidence in its profitability.
Sign up to view all
VRTX 12-Month Price Forecast
Vertex's investment case hinges on successful pipeline diversification beyond CF. The base case of 50% probability reflects steady CF growth and gradual pipeline progress, yielding returns near the average target. The bull case (30%) offers significant upside if multiple catalysts align, while the bear case (20%) captures downside from pipeline failures. The current valuation at 22.4x forward earnings is reasonable given the company's profitability and growth prospects. The stance is bullish with medium confidence because while the fundamentals are strong, the binary nature of pipeline catalysts introduces uncertainty. An upgrade to high confidence would require visible revenue from new products; a downgrade to neutral would follow a pipeline setback or CF growth below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Vertex Pharmaceuticals's 12-month outlook, with a consensus price target around $557.13 and implied upside of +16.8% versus the current price.
Average Target
$557.13
0 analysts
Implied Upside
+16.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$350 - $652
Analyst target range
Vertex is covered by 23 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.68 on a 1-5 scale, where 1 is Strong Buy). The average target price is $554.91, implying approximately 16.2% upside from the current price of $477.36. The distribution leans heavily bullish, with recent ratings from Truist Securities (Buy), UBS (Buy), RBC Capital (Outperform), and Morgan Stanley (Overweight) reaffirming positive sentiment. Only one firm, Baird, rates it Underperform, indicating a strong bullish consensus. The target price range spans from a low of $350.00 to a high of $652.00, representing a wide spread of $302.00. The high target of $652 implies 36.6% upside and likely assumes successful pipeline execution, including approval of the kidney drug and continued growth from Casgevy and the Crinetics acquisition. The low target of $350 implies 26.7% downside and may reflect risks such as CF franchise erosion, clinical trial failures, or integration challenges from the Crinetics deal. The wide spread signals high uncertainty around Vertex's pipeline-driven growth story, but the overall bullish consensus suggests analysts believe the risk/reward is favorable. Recent ratings have been stable, with no major downgrades, indicating confidence in Vertex's strategic direction.
Drowning in data?
Find the real signal!
Bulls vs Bears: VRTX Investment Factors
Vertex presents a compelling risk/reward profile: a dominant CF franchise with 86.85% gross margins and 34.5% net margins provides a stable foundation, while pipeline catalysts in kidney disease, gene therapy, and the Crinetics acquisition offer significant upside. The bull case is supported by strong financials, low beta, and bullish analyst consensus with 16.2% average upside. However, the bear case highlights decelerating CF growth, a 33% valuation premium to peers, and integration risks from the $10 billion Crinetics deal. The single most important tension is whether Vertex can successfully diversify beyond CF: if the kidney drug gets FDA approval and Casgevy ramps commercially, the stock could re-rate higher; if pipeline setbacks occur, the premium valuation could compress sharply. Currently, the evidence slightly favors the bull case given the strong balance sheet and near-term catalysts, but the wide target spread underscores the binary nature of the thesis.
Bullish
- Dominant CF Franchise with High Margins: Vertex's CF therapies generated $2.355 billion from Trikafta/Kaftrio alone in Q1 2026, contributing to a gross margin of 86.85% and net margin of 34.5%. This near-monopoly provides a stable, high-margin revenue base that funds pipeline expansion.
- Pipeline Diversification with Near-Term Catalysts: Positive Phase 3 data for the APOL1-mediated kidney drug positions it for potential FDA approval by year-end, while Casgevy showed 100% efficacy in pediatric trials. The $10 billion Crinetics acquisition adds a commercialized drug and pipeline candidate with $5 billion revenue potential.
- Strong Financial Health and Cash Flow: Vertex has a debt-to-equity ratio of 0.208, current ratio of 2.90, and trailing free cash flow of $3.71 billion. This fortress balance sheet provides ample liquidity for R&D and acquisitions without diluting shareholders.
- Analyst Consensus Bullish with Upside: 23 analysts rate Vertex a Buy (mean 1.68/5), with an average target of $554.91, implying 16.2% upside from $477.36. The high target of $652 suggests 36.6% potential if pipeline catalysts succeed.
Bearish
- CF Franchise Growth Deceleration: Q1 2026 revenue growth of 7.82% YoY decelerated from 11.5% in Q4 2025, signaling maturation of the CF market. With limited new CF patients, future growth depends entirely on pipeline success, which is uncertain.
- High Valuation Premium to Peers: Trailing P/E of 29.32x is 33% above the biotech industry average of ~22x. While justified by profitability, any pipeline setback could compress the multiple, leading to significant downside.
- Crinetics Acquisition Integration Risk: Vertex paid a 102% premium for Crinetics, totaling $10 billion. If the acquired pipeline fails to meet revenue expectations or integration challenges arise, the deal could destroy shareholder value.
- Wide Analyst Target Spread Indicates Uncertainty: Analyst targets range from $350 (26.7% downside) to $652 (36.6% upside), a $302 spread. This wide dispersion reflects high uncertainty around pipeline execution and CF franchise sustainability.
VRTX Technical Analysis
Vertex's stock is in a broad uptrend, with a 1-year price change of +107.78%, significantly outperforming the S&P 500's 16.47% gain. The current price of $477.36 sits at 63.6% of its 52-week range ($362.50 low to $533.67 high), suggesting the stock is in the middle of its range after a strong rally but not yet overextended. This positioning indicates a healthy consolidation phase following a substantial run, with room for further upside if catalysts materialize. Short-term momentum is mixed: the 1-month price change is +0.45%, while the 3-month change is +10.94%, showing a deceleration from the longer-term trend. The 1-month relative strength vs. SPY is -0.33%, indicating slight underperformance recently, but the 3-month relative strength is +7.44%, confirming that the medium-term trend remains bullish. The divergence between the 1-month flatness and the strong 1-year uptrend could signal a temporary pullback or consolidation within an ongoing bull market, rather than a trend reversal. Key support lies at the 52-week low of $362.50, while resistance is at the 52-week high of $533.67. A breakout above $533.67 would signal a resumption of the uptrend and could target new highs, while a breakdown below $362.50 would be a bearish signal, potentially indicating a deeper correction. Vertex's beta of 0.29 is remarkably low, meaning the stock is about 71% less volatile than the S&P 500, making it a defensive holding within the biotech sector and reducing the risk of sharp drawdowns.
Beta
0.29
0.29x market volatility
Max Drawdown
-23.6%
Largest decline past year
52-Week Range
$363-$534
Price range past year
Annual Return
+4.4%
Cumulative gain past year
| Period | VRTX Return | S&P 500 |
|---|---|---|
| 1m | -4.2% | +0.2% |
| 3m | +12.5% | +3.7% |
| 6m | +1.5% | +8.0% |
| 1y | +4.4% | +18.2% |
| ytd | +5.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VRTX Fundamental Analysis
Vertex's revenue trajectory remains solidly growing, with Q1 2026 revenue of $2.987 billion, up 7.82% year-over-year from $2.770 billion in Q1 2025. The multi-quarter trend shows consistent sequential growth: Q4 2025 revenue was $3.227 billion, Q3 2025 was $3.076 billion, and Q2 2025 was $2.965 billion. The CF franchise continues to drive results, with Trikafta/Kaftrio contributing $2.355 billion in the latest quarter, while Alyftrek added $424 million and other manufactured products contributed $136 million. The growth is decelerating slightly from the 11.5% YoY growth seen in Q4 2025, but the pipeline expansion into kidney disease and gene therapy provides new growth vectors. Vertex is highly profitable, with Q1 2026 net income of $1.031 billion and a net margin of 34.5%. Gross margin remains best-in-class at 86.85%, reflecting the high-margin nature of its specialty drugs. Operating margin was 38.1%, up from 22.7% in Q1 2025, demonstrating strong operating leverage as revenue scales. The company's profitability is well above industry averages for biotechnology, where many peers are unprofitable. Vertex's balance sheet is fortress-like: debt-to-equity is a mere 0.208, and the current ratio is 2.90, indicating ample liquidity. Free cash flow (FCF) for the trailing twelve months is $3.710 billion, providing significant financial flexibility for acquisitions and R&D investment. The FCF yield is approximately 3.2% based on the current market cap, which is reasonable for a growth biotech. ROE stands at 21.2%, reflecting efficient capital allocation and strong returns on shareholder equity.
Quarterly Revenue
$3.0B
2026-03
Revenue YoY Growth
+7.8%
YoY Comparison
Gross Margin
86.9%
Latest Quarter
Free Cash Flow
$3.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VRTX Overvalued?
Since Vertex has positive net income ($1.031 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 29.32x, while the forward P/E is 22.40x, based on estimated EPS of $33.22 for the next fiscal year. The gap between trailing and forward P/E implies that the market expects earnings growth of approximately 31% over the next year, which is consistent with Vertex's pipeline-driven growth narrative. Compared to the biotechnology industry average P/E of roughly 22x (based on sector data), Vertex's trailing P/E of 29.32x represents a 33% premium. This premium is justified by Vertex's superior profitability (net margin of 34.5% vs. industry average of ~15%), dominant CF market position, and promising pipeline in kidney disease and gene therapy. However, the forward P/E of 22.40x is more in line with the industry average, suggesting that the market is pricing in the expected earnings growth. Historically, Vertex's trailing P/E has ranged from 13.7x (Q3 2021) to 48.1x (Q1 2025), with the current 29.32x sitting near the middle of that range. This indicates that the stock is not excessively overvalued relative to its own history, but it is not a deep value either. The current P/E is below the 5-year average of approximately 30x, suggesting a reasonable entry point for a high-quality growth company.
PE
29.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 14x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Vertex's core CF franchise is maturing, with Q1 2026 revenue growth decelerating to 7.82% YoY from 11.5% in Q4 2025. The company's $10 billion Crinetics acquisition at a 102% premium introduces integration risk and potential goodwill impairment if pipeline candidates fail. While debt-to-equity is low at 0.208, the heavy R&D spend of $961.6 million in Q1 2026 (32.2% of revenue) means profitability is sensitive to pipeline success. The net margin of 34.5% is best-in-class, but any erosion in CF pricing or volume could compress margins significantly.
Market & Competitive Risks: Vertex's trailing P/E of 29.32x trades at a 33% premium to the biotech industry average of 22x, leaving it vulnerable to multiple compression if growth disappoints. The CF market faces potential competition from emerging therapies, though Vertex's IP portfolio provides near-term protection. With a beta of 0.29, the stock is less sensitive to macro swings, but sector rotation away from growth could still pressure the stock. Recent news highlights the binary nature of pipeline catalysts: the kidney drug Phase 3 win boosted the stock, while any negative trial readout could trigger sharp sell-offs.
Worst-Case Scenario: A combination of CF franchise erosion (e.g., new competitor approval), pipeline failures (kidney drug FDA rejection, Casgevy commercial miss), and Crinetics integration issues could drive the stock to the analyst low target of $350, representing 26.7% downside from $477.36. This scenario would imply a P/E compression to ~21x, in line with the industry average. The 52-week low of $362.50 provides a similar downside estimate of -24.1%. In such a scenario, an investor could lose approximately $127 per share, or 26.7% of their investment.
FAQ
The key risks are: 1) Pipeline failure — the kidney drug or Casgevy could miss clinical or commercial expectations, removing the primary growth catalysts. 2) CF franchise erosion — competition or pricing pressure could slow growth below 5%, compressing the valuation multiple. 3) Integration risk — the $10 billion Crinetics acquisition at a 102% premium may not deliver expected synergies, leading to write-downs. 4) Valuation risk — the trailing P/E of 29.32x leaves limited room for error; any disappointment could trigger a de-rating to the industry average of 22x, implying 25% downside. The most severe risk is a combination of CF deceleration and pipeline failure, which could drive the stock to $350 (26.7% downside).
The 12-month forecast is based on three scenarios: Bull case (30% probability) targets $530-$652, driven by FDA approval of the kidney drug and strong Casgevy uptake. Base case (50% probability) targets $470-$555, assuming steady CF growth and gradual pipeline progress. Bear case (20% probability) targets $350-$430, reflecting pipeline setbacks or CF deceleration. The most likely scenario is the base case, with the stock reaching the analyst average target of $554.91, implying 16.2% upside. Key assumptions include CF growth of 5-8%, kidney drug approval with modest initial sales, and successful Crinetics integration. The wide target range ($350-$652) underscores the binary nature of the pipeline catalysts.
Vertex's trailing P/E of 29.32x is 33% above the biotech industry average of 22x, suggesting a premium. However, this premium is justified by superior profitability (net margin 34.5% vs. industry ~15%) and a dominant market position. The forward P/E of 22.4x is in line with the industry average, indicating the market is pricing in expected earnings growth of ~31%. Historically, Vertex's trailing P/E has ranged from 13.7x to 48.1x, with the current 29.32x near the middle, suggesting it is not excessively overvalued. Overall, Vertex appears fairly valued relative to its growth prospects, with the premium on trailing earnings reflecting its high-quality earnings stream.
Vertex is a good buy for long-term investors seeking a high-quality biotech with a dominant CF franchise and promising pipeline. The stock offers a favorable risk/reward: analyst consensus is Buy with an average target of $554.91, implying 16.2% upside from $477.36. The forward P/E of 22.4x is reasonable given 34.5% net margins and 7.82% revenue growth. The biggest downside risk is pipeline failure, which could drive the stock to $350 (26.7% downside). However, the low beta of 0.29 and fortress balance sheet (debt-to-equity 0.208) provide a margin of safety. For investors with a 3-5 year horizon, Vertex offers a compelling blend of stability and growth.
Vertex is best suited for long-term investment (3-5 years) due to its pipeline-driven growth story and low beta of 0.29, which reduces short-term volatility. The stock's 1-year return of 107.78% shows strong momentum, but short-term trading is risky given the binary nature of pipeline catalysts (e.g., FDA decisions). The company pays no dividend, so total return depends on capital appreciation. For long-term investors, the combination of a dominant CF franchise and a pipeline targeting large markets (kidney disease, gene therapy) provides a clear growth trajectory. A minimum holding period of 3 years is recommended to allow pipeline catalysts to materialize and the Crinetics acquisition to contribute.
